By Fineline Cube 
Yunnan Baiyao Group Co., Ltd (SHE: 000538), a traditional Chinese medicine (TCM) company based in Kunming, announced that it has received clinical trial clearance from China’s National Medical Products Administration (NMPA) for its Category 1 chemical drug INR102. This therapeutic radiopharmaceutical is designed to treat adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with androgen receptor pathway inhibitors and taxane chemotherapy.
Drug Mechanism
INR102 combines a PSMA-targeting ligand for precise tumor localization with the beta-emitting radioisotope lutetium-177 (¹⁷⁷Lu) to deliver targeted radiation therapy. This innovative approach aims to enhance treatment precision and efficacy in patients with advanced prostate cancer.
Clinical Trial Objectives
The clinical trial will evaluate the safety, tolerability, and preliminary efficacy of INR102 in patients with mCRPC. The study is expected to provide critical data supporting the drug’s potential to address unmet medical needs in this patient population.-Fineline Info & Tech